LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Advances Cancer Drug In EU With EMA Application Validation
AstraZeneca (LSE:AZN) recently saw its stock price increase by 9% over the last quarter, a move potentially influenced by the European Medicines Agency's validation of its ENHERTU® marketing authorization application. This development complements other significant news, such as the favorable TAGRISSO trial results and regulatory approvals for DATROWAY, which could have added positive momentum. Amid these corporate achievements, broader market trends saw the Nasdaq hitting new highs,...